Cytek Biosciences (NASDAQ:CTKB) Posts Earnings Results, Beats Expectations By $0.02 EPS

Cytek Biosciences (NASDAQ:CTKB – Get Free Report) announced its earnings results on Wednesday. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.02, FiscalAI reports. Cytek Biosciences had a negative net margin of 38.98% and a negative return on equity of 12.40%. The company had revenue of $53.23 million for the quarter, compared to analysts’ expectations of $53.05 million.

Here are the key takeaways from Cytek Biosciences’ conference call:

• Revenue growth was modest and uneven: Q3 revenue rose 2% to $53.2 million, with U.S. revenue up 12% and academic and government sales up 38%; APAC revenue fell 25% year over year, while biopharma, CRO and distributor revenue declined 17%.
• High-end instrument demand was a bright spot. Combined Aurora and Aurora Evo placements increased 23%, with Evo placements nearly doubling; high-end Full Spectrum Profiling instrument revenue grew 11%.
• Gross margin improved, but adjusted EBITDA declined. Gross margin expanded nearly 600 basis points to 59%, helped by lower manufacturing overhead, material costs and tariffs; adjusted EBITDA was $0.7 million versus $2.5 million a year earlier, reflecting higher operating expenses and lower investment income.
• Cytek maintained its full-year revenue outlook and narrowed its 2026 guidance to $208 million–$211 million. Management expects Q4 revenue to rise meaningfully with seasonal purchasing and projects adjusted EBITDA around break-even for the year.
• Patent litigation remains unresolved, but management says operations are unaffected. A jury found infringement under the doctrine of equivalents on one claim, and Cytek is seeking to overturn the verdict; the company said it can continue selling and shipping products and expects litigation expenses to decrease in Q4.

Cytek Biosciences Trading Down 4.2%

NASDAQ:CTKB traded down $0.25 on Thursday, hitting $5.63. 275,576 shares of the stock were exchanged, compared to its average volume of 1,084,701. The stock has a market cap of $732.18 million, a PE ratio of -8.95 and a beta of 1.15. Cytek Biosciences has a fifty-two week low of $3.31 and a fifty-two week high of $6.34. The stock has a fifty day moving average of $5.35 and a 200-day moving average of $4.67.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Cytek Biosciences in a research report on Monday, September 21st. Stephens reaffirmed an “overweight” rating and set a $6.00 target price on shares of Cytek Biosciences in a research note on Friday, October 23rd. Finally, Morgan Stanley set a $5.00 price objective on Cytek Biosciences in a research report on Friday, August 7th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Cytek Biosciences currently has a consensus rating of “Hold” and a consensus price target of $5.88.

Read Our Latest Analysis on CTKB

Cytek Biosciences Company Profile

(Get Free Report)

Cytek Biosciences, Inc develops and commercializes cell analysis solutions for biomedical research, clinical research and biopharmaceutical applications. The company focuses on spectral flow cytometry, a technology that enables researchers to analyze multiple characteristics of individual cells and identify complex cell populations.

Its product portfolio includes the Aurora and Northern Lights spectral flow cytometers, compact and specialized instruments, cell sorters, software and a range of fluorescent reagents.

Featured Articles

• Five stocks we like better than Cytek Biosciences
• The Fed Is Split on Rates—Why These 2 Treasury ETFs Could Have an Edge
• Gold’s 2026 Pullback Raises a Bigger Question: Buy the Metal or the Miners?
• Matador Resources Insider Buying and the Case for a Dividend Stock Rebound
• Datadog’s Post-Earnings Sell-Off: A Buying Opportunity in Plain Sight?

Receive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.